Biological characterization and selection criteria of adjuvant chemotherapy for early breast cancer: experience from the Italian observational NEMESI study by Clavarezza, Matteo et al.
Clavarezza et al. BMC Cancer 2012, 12:216
http://www.biomedcentral.com/1471-2407/12/216RESEARCH ARTICLE Open AccessBiological characterization and selection criteria
of adjuvant chemotherapy for early breast cancer:
experience from the Italian observational NEMESI
study
Matteo Clavarezza1,16*, Giorgio Mustacchi2, Andrea Casadei Gardini3, Lucia Del Mastro4, Andrea De Matteis5,
Ferdinando Riccardi6, Vincenzo Adamo7, Enrico Aitini8, Domenico Amoroso9, Paolo Marchetti10, Stefania Gori11,
Francesco Carrozza12, Evaristo Maiello13, Francesco Giotta14, Davide Dondi15 and Marco Venturini1Abstract
Background: International treatment guidelines recommend administration of adjuvant chemotherapy in early
breast cancer based on clinical, prognostic and predictive parameters.
Methods: An observational study (NEMESI) was conducted in 63 Italian oncology centres in patients with early
breast cancer. Age, performance status, concomitant disease, menopausal status, histology, tumor dimension (pT),
axillary lymph node status (pN), grading (G), estrogen and progesterone receptor (ER and PgR), proliferative index
(ki67 or MIB-1), human epidermal growth factor receptor 2 (HER2) and type of adjuvant treatment were recorded.
The primary objective of the study was to define parameters influencing the decision to prescribe adjuvant
chemotherapy and the type of chemotherapy.
Results: Data for 1894 patients were available. 69.0% postmenopausal, 67.0% pT1, 22.3% pTmic/pT1a/pT1b, 61.0%
pN0, 48.7% luminal A, 18.1% luminal B, 16.1% HER2 positive, 8.7% triple negative, 8.4% unknown. 57.8% received
adjuvant chemotherapy: 38.1% of luminal A, 67.3% luminal B, 88.2% HER2-positive, 97.6% triple negative. Regimens
administered: 9.1% CMF-like, 48.8% anthracyclines, 38.4% anthracyclines plus taxanes, 3.7% taxanes alone. Increasing
pT/pN and, marginally, HER2-positive were associated with the prescription of anthracyclines plus taxanes.
Suboptimal schedules (CMF-like or AC/EC or FEC-75) were prescribed in 37.3% receiving chemotherapy, even in
HER2-positive and triple negative disease (36.5% and 34.0%, respectively).
Conclusions: This study showed an overprescription of adjuvant chemotherapy for early breast cancer, particularly
referred to luminal A. pT, pN and, marginally, HER2 were the principal determinants for the choice of chemotherapy
type. Suboptimal chemotherapy regimens were adopted in at least one third of HER2-positve and triple negative.* Correspondence: matclava78@libero.it
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Breast cancer is the most common malignancy in
women in Italy and its incidence is similar to the data
from other tumor registry of other countries such as
NORDCAN [1], SEER [2], UK [3]. Breast cancer inci-
dence increased until 2000. From 2003 breast cancer in-
cidence in USA is little decreasing for the reduced
administration of hormonal replacement therapy [4,5],
while in Italy from 2000 incidence is stable above all be-
cause of completed extension of mammographic screen-
ing [6-8]. In Italy breast cancer incidence vary according
to geographic location. In fact, it is 115 cases per
100,000 women (45000 new cases each year), consisting
of 29% of all new diagnosis of malignancies, with signifi-
cant differences between North, Centre and South Italy:
123, 103 and 87 new cases are diagnosed each year per
100,000 women, respectively [9]. This difference is due
to the different extension of mammographic screening
and different risk factors for breast cancer, above all the
different life-styles, with North Italy with a life-style
more similar to North Europe and United States com-
pared to South Italy.
Breast cancer causes more than 11,000 deaths each
year in Italy, 24.2 cases per 100,000 women/year, with
no relevant difference between North, Centre and South
Italy (24.8, 21.1, 24.7 deaths for breast cancer per
100000 women/year), even if 5-year overall survival is
between 85% and 87% in North and Centre Italy, com-
pared to 81% of South Italy [9]. This difference is prob-
ably due to the different possibility to access to
screening program [10].
Optimal management of patients with early breast can-
cer involving integrated treatments encompassing sur-
gery, radiotherapy and systemic therapy had led, together
to breast cancer screening, to mortality reduction [11].
Tumor stage, histological grading, estrogen and proges-
terone receptor (ER and PgR), proliferative index and
human epidermal growth factor receptor 2 (HER2) aid in
tumor evaluation and often dictate the choice of systemic
treatment. Evidence-based international treatment guide-
lines including those of the NCCN (National Compre-
hensive Cancer Network) [12], the National Cancer
Institute (NCI) [13] and the St. Gallen Consensus Report
[14] recommend using adjuvant therapy for patients with
early breast cancer. In particular adjuvant chemotherapy
is not recommended for endocrine-sensitive breast can-
cer (ER-positive, low proliferative index and HER2 nega-
tive) with low recurrence risk. On the contrary, it is
particularly indicated in at least one of the following bio-
logical conditions: ER-negative, HER2 positive, high pro-
liferative index (>30%), grading 3. It remains unclear
which is the role of adjuvant chemotherapy in endo-
crine sensitive breast cancer with intermediate recur-
rence risk (tumor diameter of 2 cm or more or node-positive from one to three lymph nodes), grading 2,
proliferation index below 30%.
The aim of this retrospective observational study is to
analyze factors influencing the choice for adjuvant
chemotherapy, type of chemotherapy and schedules of
chemotherapy in patients with early breast cancer in
order to improve knowledge about the therapeutic man-
agement of early breast cancer in Italy and verify the ad-
herence to international guidelines.
Methods
Study design
NEMESI is a retrospective observational study con-
ducted at oncology unit throughout Northern, Central
and Southern Italy. Institution types included IRCCS
(Istituto di Ricovero e Cura a Carattere Scientifico), pub-
lic hospital and private hospitals with oncology unit,
public and private university hospitals. Centres were
selected from the 386 censed centres (complex oncology
units or simple oncology units with or without breast
units) reported in the White Book of the Italian Associ-
ation of Medical Oncology (AIOM 2006) in order to
covering the whole spectrum of treatment of breast-
cancer patients [15]. Centres were selected to represent
Italian scenario on the basis of three criteria. The first
was a geographic criteria: each area (North, Center and
South-Islands) was to be proportional to the centres
included in Libro Bianco (North Italy: 33 participating
centres of 179 censed centres of Libro Bianco, which rep-
resent 52.4% of all centres of the study and 46.4% of all
centres of Libro Bianco, respectively; Central Italy: 11
participating centres of 92 censed centres of Libro
Bianco, which represent 17.5% of all centres of the study
and 23.8% of all centres of Libro Bianco, respectively;
Southern Italy and Islands: 19 participating centres of
108 of all centres of Libro Bianco, which means 30.1% of
all centres of the study and 29.8% of all centres of Libro
Bianco, respectively). The second selection criterion was
that each type of Institution must to be rapresentated
proportionally to Libro Bianco (7.5% of Private Hospital,
7.5% of IRCCS, 70% of Public or Private Hospital with
Oncology Unit and 15% of public and Private University
Hospital). The third criterion was to select centres with
at least 120 new cases attending each oncologic centre in
2008 in order to ensure anonymity as required by Italian
regulations governing observational studies (AIFA docu-
ment, dated 30 March 2008).
Patients were eligible for the study if they met the fol-
lowing criteria: women, age ≥18 years; histological diag-
nosis of stage I, II or III breast cancer according to the
tumor, node, metastasis (TNM) classification devised by
the American Joint Committee on Cancer (AJCC) ver-
sion VI [16]; undergone surgery; prescribed and received
at least one cycle of adjuvant chemotherapy and/or
Table 1 Demographic data of valuable patients
Demographic characteristics n (%)
Total 1894 (100)
Median age range (years)
≥18− 34 30 (1.6)
≥35− 49 469 (24.8)
≥50− 69 984 (51.9)
≥70 411 (21.7)
ECOG* Performance Status
0 1661 (87.7)
1 179 (9.5)
2 25 (1.3)
3 6 (0.3)
Missing 23 (1.2)
Menopausal status
Premenopausal 566 (29.9)
Postmenopausal 1307 (69.0)
Missing 21 (1.1)
Second diagnosis of breast cancer
Yes 86 (4.5)
No 1802 (95.2)
Not reported 6 (0.3)
* ECOG= Eastern Cooperative Oncology Group.
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data for the following parameters: tumor dimension
(pT), axillary lymph node status (pN), grading (G), ER
and PgR, HER2, and proliferative index (Ki67 or MIB-1).
However, patients with lacking of one or more of these
parameters were eligible and included in the analysis in
order to obtain a real photograph of data available for
the process choice of adjuvant chemotherapy. Candi-
dates for adjuvant therapy with trastuzumab and/or
radiotherapy on the residual breast or thoracic wall, re-
gional supraclavear, internal breast lymph node stations
were also eligible. Exclusion criteria were: use of neo-ad-
juvant therapy, diagnosis of metastatic breast cancer
(stage IV) or in-situ carcinoma. Data were retrieved
retrospectively by each site from the patients’ clinical
records.
The protocol was reviewed by the independent ethics
committee of the coordinating center. Notification of
the study was also sent to the ethics committees of each
participating center, as required by Italian regulations
governing observational studies (AIFA document, dated
30 March 2008). The protocol complied with the Declar-
ation of Helsinki.
Sample size determination and data collection
Each center was requested to collect, by December 2009,
data from a minimum of 10 and a maximum of 30
patients with breast cancer attending the center between
1 January 2008 and 30 June 2008. Each center had two
particular requests in the selection of cases. First: data
were collected by each center in a consecutive manner
from a chronological point of view for patients attending
oncologic units in the indicated period in order to
exclude any selection bias. Second: each center had the
request to collect data from at least 33% of patients re-
ceiving adjuvant chemotherapy. This particular inclusion
criterion was necessary in order to obtain a sufficient
number of patients receiving adjuvant chemotherapy in
order to analyze, from a statistical point of view, para-
meters involving the choice to administer adjuvant
chemotherapy. Data were collected on an electronic
clinical report form and were submitted for automatic
checks to assess completeness, correctness and internal
coherence.
Statistical analysis
Continuous variables were summarized using descriptive
statistics, including number of subjects, mean, standard
deviation, median, minimum, 25th percentile, 75th per-
centile and maximum. For categorical variables, sum-
maries included counts of subjects and percentages.
Multivariate logistic regression analysis was used to as-
sess the relationship between clinical and demographic
variables, choice of adjuvant chemotherapy, the regimenadministered, and the following covariates: patient age,
menopausal status, previous breast cancer history,
ECOG performance status, surgery type, tumor stage,
ER, PgR, HER2 and proliferative index. ER/PgR status
and proliferative index were included in the model as
categorical variables as well as continuous variables. A
stepwise procedure was used with a significance level of
p = 0.05 to retain variables in the model. Odds ratio
(OR) estimates and their 95% confidence intervals (CIs)
were also calculated. Two-sided 95% CIs for proportions
and means are reported where applicable. The Statistical
Analysis System version 9.1.3 for Windows (SAS Insti-
tute Inc., Cary, NC, USA) was used for statistical
analysis.
Results
Demographic and breast cancer biological characteristics
Data were collected from a total of 1894 patients in the
63 participating Italian oncology centres. Demographic
data are summarized in Table 1. Tumor characteristics
and biological classification based on ER, PgR, Ki67 or
MIB, HER2 are summarized in Table 2.
The median tumor diameter was 1.7 cm (range: 0.1 to
35.0 cm). Overall 22.3% of tumors were ≤1.0 cm in
diameter; pT1c was the more frequent breast cancer pT
stage: 44.7%. The median number of involved lymph
nodes was 1 (range: 0 to 47), 61.0% were pN0 and 9.9%
pN2 or pN3.
Table 2 Tumor characteristics of evaluable patients
Disease characteristic
(n = 1894)
Total, n (%) CT, n (%) No CT, n (%)
Tumor dimensions (pT)
• pT1mic-pT1a-pT1b 422 (22.3%) 132 (31.3%) 290 (68.7%)
• pT1c 846 (44.7%) 515 (60.9%) 331 (39.1%)
• pT2-pT3-pT4b 626 (33.0%) 448 (71.6%) 178 (28.4%)
Axillary lymph node status (pN)
• pN0 1155 (61.0%) 502 (43.5%) 653 (56.5%)
• pN1 551 (29.1%) 422 (76.6%) 129 (23.4%)
• pN2 119 (6.3%) 106 (89.1%) 13 (10.9%)
• pN3 69 (3.6%) 65 (94.2%) 4 (5.8%)
Estrogen and Progesterone Receptor (ER/PgR)
• ER or PgR-positive (≥1%) 1619 (85.5%) 829 (51.2%) 790 (48.8%)
• ER and PgR 0% 274 (14.5%) 266 (97.1%) 8 (2.9%)
• Unknown 1 (0.1%) 0 (0.0%) 1 (100%)
Proliferative index (Ki67 or MIB-1)
• Low (≤20%) 1150 (60.7%) 499 (43.4%) 651 (56.6%)
• High (>20%) 691 (36.5%) 562 (81.3%) 129 (18.7%)
• Unknown 53 (2.8%) 34 (64.2%) 19 (35.8%)
HER2
• Positive 305 (16.1%) 269 (88.2%) 36 (11.8%)
• Negative 1463 (77.2%) 761 (52.0%) 702 (48.0%)
• Unknown 126 (6.7%) 65 (51.6%) 61 (48.4%)
Biological type
• Luminal A 923 (48.7%) 352 (38.1%) 571 (61.9%)
• Luminal B 342 (18.1%) 230 (67.3%) 112 (32.7%)
• HER2 305 (16.1%) 269 (88.2%) 36 (11.8%)
• Triple negative 165 (8.7%) 161 (97.6%) 4 (2.4%)
• Unknown 159 (8.4%) 83 (52.2%) 76 (47.8%)
Luminal A: ER or PgR ≥1% and proliferative index ≤20% and HER2-negative.
Luminal B: ER or PgR ≥1% and proliferative index >20% and HER2-negative.
HER2-positive: HER2-positive (IHC 3+, or IHC 2+ with HER2 amplified, HER2
amplified independently from IHC) independently from the values of ER, PgR,
proliferative index.
Triple negative: ER and PgR both 0% and HER2 negative independently from
the proliferative index.
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was ≥10% in 82.7%, ER ≥1% in 84.9%. When also consid-
ering PgR, ER or PgR were ≥1% in 85.5%, ER or PgR
≥10% in 83.5%, ER and PgR both <10% in 16.4%, ER
and PgR both 0% in 14.5%.
HER2 was positive in 16.1% of study population, nega-
tive in 77.2%, unknown in 6.7%. According to immuno-
histochemistry, 13.5% were HER2 3+, 11.6% HER2 2+,
20.5% HER2 1+ and 47.8% HER2 0; an amplification test
(FISH, SISH, or CISH) was performed in 22.6% cases.
86.8% HER2 2+ were analyzed with amplification test, of
which 26.3% HER2 resulted as amplified.
Proliferative index was known in 97.2%. Among these
patients, proliferative index was determined with ki67 in
67.2% and with MIB-1 in 32.8%. Ki67 or MIB-1 was≤20% in 62.5%, from 21% to 30% in 16.3%, >30% in
21.2% cases. Considering different cut-off values, ≤14%
in 42.5%, >14% in 57.5%.
Factors affecting choice of adjuvant chemotherapy and
type of chemotherapy
57.8% (n = 1095) of the study population received adju-
vant chemotherapy. A summary of adjuvant chemother-
apy type and the administration schedules are listed in
Table 3. Table 4 presents factors associated with chemo-
therapy prescription.
Age was a strong determinant for chemotherapy pre-
scription. Overall, there were no differences in the
chemotherapy type prescribed according to age, al-
though use of CMF-like regimen was more common
among patients aged ≥70 years. While CMF-like therapy
was prescribed in 9.1% of the overall population receiv-
ing adjuvant chemotherapy, the probability increased to
27.0% in patients aged ≥70 years; however, the difference
was not statistically significant due to low numbers.
Menopausal status influenced the decision to use adju-
vant chemotherapy: 74.9% of premenopausal and 50.3%
of postmenopausal patients received adjuvant chemo-
therapy, respectively (OR: 2.95, CI95%: 2.37-3.67, p
< 0.0001). Premenopausal patients were more often trea-
ted with adjuvant anthracyclines, with or without tax-
anes, than postmenopausal patients (92.7% versus 83.7%:
OR=2.46, CI95%= 1.62-3.75, p< 0.0001). This differ-
ence was not significant considering anthracyclines
alone: 49.8% versus 48.5%, respectively (p = 0.68), but
was significant for anthracyclines plus taxanes: 42.9%
versus 35.3%, respectively (OR= 1.38, CI95%= 1.08-1.77,
p = 0.011).
Tumor stage at first diagnosis greatly influenced the
decision to use adjuvant chemotherapy as shown in
Table 4. The pT category influenced the type of chemo-
therapy administered: the use of CMF-like therapy
decreased from 13.6% of pT1mic/pT1a/ pT1b to 9.9% of
pT1c and to 6.9% of pT2/pT3/pT4b (pT1mic/pT1a/
pT1b versus pT2/pT3/pT4b: OR= 2.12, CI95%= 1.15-
3.94; pT1c versus pT2/pT3/pT4b: OR= 1.48, CI95%=
0.93-2.36, p = 0.047) At the same time anthracyclines
plus taxanes increased from 25.8% of pT1mic/pT1a/
pT1b to 34.6% of pT1c and to 46.4% of pT2/pT3/pT4b
(pT2/pT3/pT4b versus pT1mic/pT1a/pT1b: OR=2.50,
CI95%= 1.62-3.85; pT1c versus pT1mic/pT1a/pT1b:
OR=1.52, CI95%= 0.99-2.34, p< 0.0001). The use of
anthracyclines alone decreased from pT1mic/pT1a/pT1b
to pT1c (58.3% and 50.9%, respectively) and to pT2/
pT3/pT4b (43.5%) (pT1mic/pT1a/pT1b versus pT2/
pT3/pT4b: OR=1.82 CI95%= 1.23-2.69; pT1c versus
pT2/pT3/pT4b: OR= 1.34 CI95%= 1.04-1.73; p = 0.005).
A correlation was also seen between pN staging and
higher rates of adjuvant chemotherapy prescription.
Table 3 Type and schedules of adjuvant chemotherapy
prescribed (n =1095)
Type of chemotherapy N (%)
CMF-like 100 (9.1)
• Anthracyclines alone (without Taxanes) 534 (48.8)
• Anthracyclines plus Taxanes 420 (38.4)
• Taxanes alone (without Anthracyclines) 41 (3.7)
Type of Taxane
• Docetaxel 359 (32.8)
• Paclitaxel 102 (9.3)
Main chemotherapeutic schedules administered
• Oral classical CMF 6 cycles 24 (2.2)
• CMF 6 cycles iv day 1 and 8 q28d 53 (4.8)
• CMF 6 cycles iv day 1 q21d 9 (0.8)
• CMF 3–4 cycles iv day 1 and 8 q28d 11 (1.0)
• AC 4 cycles 89 (8.1)
• AC 6 cycles 27 (2.5)
• E90C 4 cycles 56 (5.1)
• E75C 4 cycles 9 (0.8)
• FE75C 6 cycles 131 (12.0)
• FE90C 6 cycles 95 (8.7)
• FE100C 6 cycles 29 (2.6)
• FAC 6 cycles 8 (0.7)
• Canadian CEF 6 cycles 16 (1.5)
• Epidoxorubicin 4 cycles – CMF 4 cycles 5 (0.5)
• AC 4 cycles – CMF 3 cycles 15 (1.4)
• FEC 3 cycles - Docetaxel 3 cycles 118 (10.8)
• AC/EC 4 cycles - Docetaxel 4 cycles 127 (11.6)
• TAC 6 cycles +G-CSF 29 (2.7)
• AC/EC 4 cycles - Paclitaxel q3wks 4 cycles 39 (3.6)
• FEC/EC 4 cycles - weekly Paclitaxel x 12 43 (3.9)
• A/EP 4 cycles – CMF 4 cycles 7 (0.6)
• ET 6 cycles 12 (1.1)
• TC 4 cycles 19 (1.7)
• TC 6 cycles 8 (0.7)
• Others 116 (10.6)
C= Cyclophosphamide; M=Methotrexate; F = Fluorouracil; A =Doxorubicin;
E = Epirubicin; P = Paclitaxel; T =Docetaxel.
Table 4 Summary of the results of the multivariate
logistic model analysis that evaluated the probability of
being treated with adjuvant chemotherapy (n= 1894)
Variable OR (95%CI) p value
Age range (years) <0.0001
≥70 1
≥50-69 16.3 (10.4-25.5)
≥35-49 46.8 (27.5-79.5)
≥18-34 553 (NE*)
pT <0.0001
pT1mic/pT1a/pT1b 1
pT1c 3.3 (2.2-4.8)
pT2/pT3/pT4 6.5 (4.2-10.2)
pN <0.0001
pN0 1
pN1 7.6 (5.4-10.7)
pN2 45.9 (17.9-117.9)
pN3 28.2 (8.1-97.9)
Tumor grading <0.0001
G1 1
G2 2.8 (1.7-4.6)
G3 7.2 (4.1-12.7)
Estrogen receptor <0.0001
Positive 1
Negative 24.1 (4.9-119.5)
Biological type <0.0001
Luminal A 1
Luminal B 2.1 (1.5-3.1)
HER2 10.3 (6.1-17.6)
Triple negative 4.5 (0.6-31.9)
* CI not calculable due to the small sample size.
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tus: 19.9% of pN0 patients with prescription of adjuvant
chemotherapy received anthracyclines plus taxanes, in-
creasing to 45.0% for pN1 patients and 76.0% in pN2/
pN3 patients (pN1 versus pN0: OR= 3.29, CI95%= 2.46-
4.41; pN2-pN3 versus pN0: OR= 12.75, CI95%= 8.43-
19.28; p< 0.0001). At the same time the use of CMF-like
regimens decreased with higher pN: 13.3% of pN0
patients compared to 5.6% of lymph-node positive (pN1-
pN2-pN3) (OR=2.61, CI95%= 1.69-4.04, p< 0.0001).
The use of anthracyclines alone decreased from 63.7% of
pN0, to 44.8% of pN1 and to 14.6% of pN2-pN3 (pN0versus pN2-pN3: OR= 10.26, CI95%= 6.47-16.28; pN1
versus pN2-pN3: OR= 4.74, CI95%= 2.97-7.54,
p< 0.0001).
Combining pathological stage (IA, IB, II, III) with bio-
logical characteristics of breast cancer (luminal A, lu-
minal B, HER2, triple negative) (Table 5) we found that
decision for prescribing adjuvant chemotherapy is condi-
tioned by both variables. Increasing pathological stage is
associated with more administration of adjuvant chemo-
therapy independently by biological subtype. In particu-
lar, in luminal A 28.6% of patients with pT1 and pN0
and 56.2% in stage II received adjuvant chemotherapy.
Compared to luminal A disease, luminal B received
chemotherapy more frequently; stage IA: 30.3% versus
6.0% (OR= 6.78, 95%CI = 2.64-17.43, p< 0.0001); stage
IB: 50.6% versus 22.6 (OR= 3.50, 95%CI = 2.10-5.84, p
< 0.0001); stage II: 76.0% versus 56.2% (OR= 2.47, 95%
CI = 1.65-3.71, p< 0.0001); stage III: 90.2% versus 81.0%
(p = 0.16).
Table 5 Prescription of adjuvant chemotherapy according to biological type and stage. Chi square test was significant
(p< 0.0001) for each biological subtype
Stage Luminal A Luminal B HER2 Triple Negative
CT yes, N (%) CT no, N (%) CT yes, N (%) CT no, N (%) CT yes, N (%) CT no, N (%) CT yes, N (%) CT no, N(%)
IA* 12 (6.0%) 187 (94.0%) 10 (30.3%) 23 (69.7%) 25 (64.1%) 14 (35.9%) 17 (81.0%) 4 (19.0%)
IB** 59 (22.6%) 202 (77.4%) 44 (50.6%) 43 (49.4%) 77 (88.5%) 10 (11.5%) 56 (100%) 0 (0%)
II*** 213 (56.2%) 166 (43.8%) 130 (76.0%) 41 (24.0%) 122 (93.1%) 9 (6.9%) 75 (100%) 0 (0%)
III**** 68 (81.0%) 16 (19.0%) 46 (90.2%) 5 (9.8%) 45 (93.8%) 3 (6.3%) 13 (100%) 0 (0%)
Total 352 (38.1%) 571 (61.9%) 230 (67.3%) 112 (32.7%) 269 (88.2%) 36 (11.8%) 161 (97.6%) 4 (2.4%)
* Stage IA: pT1mic/pT1a/pT1b and pN0 ** Stage IB: pT1c and pN0 *** Stage II: pT1 and pN1, pT2/pT3 and pN0, pT2 and pN1 **** Stage III: all pN2, all pN3, all pT4,
pT3 and pN1.
Table 6 Type of chemotherapy prescribed according to
biological type
Type of
chemotherapy
Luminal A Luminal B HER2 Triple
Negative
CMF 40 (11.4%) 18 (7.8%) 11 (4.1%) 17 (10.6%)
Anthracyclines 169 (48.0%) 116 (50.4%) 137 (50.9%) 76 (47.2%)
Anthracyclines-
Taxanes
129 (36.6%) 85 (37.0%) 117 (43.5%) 59 (36.6%)
Taxanes 14 (4.0%) 11 (4.8%) 4 (1.5%) 9 (5.6%)
Total 352 (100%) 230 (100%) 269 (100%) 161 (100%)
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chemotherapy more often compared to patients with ER
or PgR ≥1% (97.1% versus 52.1%, respectively; OR=
31.69, CI95%= 15.58-64.44, p< 0.0001). There were no
differences in the type of adjuvant chemotherapy with
respect to ER/PgR status: CMF-like therapy was pre-
scribed in 9.8% and 8.9% in ER and PgR 0% and ER or
PgR ≥1% (p = 0.67), respectively; anthracyclines without
taxanes: 50.4% and 48.3%, respectively (p = 0.55); anthra-
cyclines plus taxanes: 36.1% and 39.1%, respectively
(p = 0.38); taxanes alone: 3.8% and 3.7%, respectively
(p = 0.99). Between triple negative, 97.6% was treated
with adjuvant chemotherapy: 81.0% stage IA compared
to 100% of stage IB, II, III (Table 5).
64.1% of patients with HER2-positive disease received
adjuvant chemotherapy with a tumor diameter until
1 cm of diameter (stage IA). In HER2 disease stage IB +
II + III 90.7% of HER2-positive breast cancer patients
received adjuvant chemotherapy (HER2 stage IB + II + III
versus HER2 stage IA: OR= 6.21, CI95%= 2.83-13.64, p
< 0.0001). In particular, in stage IA HER2-positive dis-
ease, 85.7% of hormonal receptors negative versus 52.0%
of hormonal receptor positive received adjuvant
chemotherapy.
HER2 status determined the choice of a regimen con-
taining anthracyclines (with or without taxanes): 94.4%
HER2-positive cases versus 85.0% HER2-negative (OR=
2.98, CI95%= 1.71-5.21, p = 0.0001). This data must be
particularly applied for regimens with anthracyclines
plus taxanes (43.5% versus 36.6%, respectively: OR=
1.33, CI95%= 1.01-1.76, p = 0.048) but not for regimens
containing anthracyclines alone without taxanes (50.9%
versus 48.4%, respectively, p = 0.47).
Analyzing HER2 as compared to other biological
subtype (Table 6), prescription of CMF was constant
between luminal A (11.4%), luminal B (7.8%) and
triple-negative (10.6%), while it was little decreasing in
HER2-positive disease (4.1%) (luminal A+B+ triple nega-
tive versus HER2: OR 2.63 CI95%: 1.38-5.04, p = 0.004). At
the same time there is an increasing use of anthracyclines
and taxanes in HER2-positive disease (43.5%) versusluminal A (36.6%), luminal B (37.0%), triple negative
(36.6%). This difference was borderline significant (HER2+
versus luminal A+B+ triple negative; p = 0.06).
Combining pathological stage with biological charac-
teristics (Table 7) we noted that administration of
anthracyclines and taxanes increased with increasing
pathological stage independently from biological sub-
type. At the same time the administration of anthracy-
clines alone decreases with increasing pathological stage.Discussions
The results of this observational study, conducted
throughout oncologic centres of Northern, Central and
Southern Italy, is representative of Italy with respect to
the choice of adjuvant chemotherapy for breast cancer.
The first important consideration is about demography
and biology of breast cancer of this population study. In
fact, most patients (85.5%) had ER or PgR-positive (≥1%)
breast cancer, while only 14.5% had both ER and PgR
0%. Triple negative cases were 8.7%, 16.1% HER2-posi-
tive independently from hormonal receptors status.
These results are probably influenced by a high propor-
tion of postmenopausal patients (nearly 70%) and by
those aged ≥70 years (21.7% of the population study). In
the previous reported observational study conducted by
Cazzaniga et al. between 2000 and 2004 [17], elderly
patients were 18.5%, despite the biological characteristics
being similar to this study.
Table 7 Prescription of the type of chemotherapy based
on pathological stage and biology
Stage CMF-like Anthracyclines Anthracyclines
+ Taxanes
Taxanes
Luminal A
IA* 3 (25.0%) 8 (66.7%) 0 (0%) 1 (8.3%)
IB** 16 (27.1%) 36 (61.0%) 7 (11.9%) 0 (0%)
II*** 16 (7.5%) 113 (53.1%) 75 (35.2%) 9 (4.2%)
III**** 5 (7.4%) 12 (17.6%) 47 (69.1%) 4 (5.9%)
Total 40 (11.4%) 169 (48.0%) 129 (36.6%) 14 (4.0%)
Luminal B
A* 1 (10.0%) 9 (66.7%) 0 (0%) 0 (0%)
IB** 7 (15.9%) 31 (61.0%) 7 (11.4%) 1 (2.3%)
II*** 10 (7.7%) 67 (53.1%) 44 (33.8%) 9 (6.9%)
III**** 0 (0%) 9 (17.6%) 36 (78.3%) 1 (2.2%)
Total 18 (7.8%) 116 (50.4%) 85 (37.0%) 11 (4.8%)
HER2
IA* 0 (0%) 22 (88.0%) 2 (8.0%) 1 (4.0%)
IB** 4 (5.2%) 54 (70.1%) 18 (23.4%) 1 (1.3%)
II*** 4 (3.3%) 55 (45.1%) 61 (50.0%) 2 (1.6%)
III**** 3 (6.7%) 6 (13.3%) 36 (80.0%) 0 (0%)
Total 11 (4.1%) 137 (50.9%) 117 (43.5%) 4 (1.5%)
Triple negative
IA* 4 (23.5%) 8 (47.1%) 4 (23.5%) 1 (5.9%)
IB** 8 (14.3%) 30 (53.6%) 14 (25.0%) 4 (7.1%)
II*** 3 (4.0%) 38 (50.7%) 32 (42.7%) 2 (2.7%)
III**** 2 (15.4%) 0 (0%) 9 (69.2%) 2 (15.4%)
Total 17 (10.6%) 76 (47.2%) 59 (36.6%) 9 (5.6%)
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the current study there is a lower incidence of high-risk
nodal disease (pN2-pN3), which decreased from 17.1%
of NORA to 9.9% of NEMESI study (p = 0.0001). This is
probably due to more extensive use of breast cancer
screening in recent years in Italy. Probably, for the same
reason, pT1 increased from 59.7% of patients in NORA
to 67.0% of NEMESI (p< 0.0001).
These demographical, pathological and biological char-
acteristics seem to be in contrast with the high rate of
adjuvant chemotherapy prescription. 57.8% of the popu-
lation study received adjuvant chemotherapy. Population
study was composed by 85% of endocrine responsive
breast cancers, 84% of HER2 negative, 61% of node-
negative and 2 of 3 cases with tumor diameter inferior
to 2 cm, 22.3% ≤1 cm. International guidelines recom-
mend the use of adjuvant chemotherapy on the basis of
all prognostic and predictive parameters but in general it
is not recommended for patients with pT1, pN0, ER-
positive, low proliferation index, HER2 negative breast
cancer. We noted that, overall, 38.1% of luminal A popu-
lation was treated with adjuvant chemotherapy: 6% instage IA, 22.6% in stage IB, 56.2% in stage II, 81.0% in
stage III. It means that 33.8% of luminal A with low
(pT1 pN0) or intermediate recurrence risk (pT2/pT3
pN0 or pN1) was treated with adjuvant chemotherapy.
25% of entire study population receiving adjuvant
chemotherapy was luminal A with low or intermediate
risk recurrence. This fact underlines an overtreatment
and over prescription with adjuvant chemotherapy. In
fact, luminal A is recognized as the less sensitive breast
cancer subtype to adjuvant chemotherapy. The cut-off
for luminal A was set to a proliferative index ≤20%. As
indicated by Cheang et al., ki67 of 14% is considered the
proliferation index able to distinguish luminal A versus
luminal B [18]. Modifying the cut-off value of prolifera-
tive index from 20% to 14% in order to distinguish be-
tween luminal A versus luminal B we obtained similar
data: 29.5% of luminal A with stage IA, IB, II was treated
with adjuvant chemotherapy and OR for the use of adju-
vant chemotherapy in luminal B versus luminal A was
1.95 (OR= 1.40-2.72) similar to that reported in Table 4.
NEMESI study identified tumor and patient character-
istics that were important determinants in the decision
to prescribe a chemotherapy regimen and the choice of
chemotherapy type. Whereas adjuvant chemotherapy
prescription by Italian oncologists is influenced by prog-
nostic and predictive parameters, type of adjuvant
chemotherapy is significantly influenced by age, meno-
pausal status and above all by the risk of recurrence (pT
and pN), but not by biological predictive factors. In fact,
prescription of CMF-like regimen decreases with in-
creasing pT and pN in favor of the use of anthracyclines
plus taxanes. In particular, as previously reported, con-
sidering small tumors pT1a and pT1b compared to lar-
ger tumors, CMF-like prescription decreases from 14.2%
to 9.9% of pT1c and 6.9% of pT2, pT3, pT4b [19]. More
recurrence risk is, more is the use of the most effective
regimen anthracyclines plus taxanes. The choice for
anthracyclines plus taxanes should be considered not on
the basis of pT and pN but on the basis of sensitiveness
to chemotherapy. As indicated by St. Gallen guidelines,
luminal B, HER2 and triple negative should receive both
anthracyclines and taxanes, which, on the contrary, are
treated with this regimen in only 37.0%, 43.5% and
36.6% of cases, respectively.
Another important issue is about older age and prescrip-
tion of the type of adjuvant chemotherapy. In fact, admin-
istration of CMF-like regimen was more frequently used
for women aged ≥70 (27.0%) than for women under 70
(9.1%) and, as previously reported, this percentage
increased until 50% considering only pT1a and pT1b
tumors [19]. This choice is in contrast with data from ran-
domized trials conducted in elderly women in whom
CMF-like was demonstrated to be more toxic and less feas-
ible compared to anthracyclines, like AC regimen [20].
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little influencing the choice of chemotherapy type is
HER2. In HER2-positive breast cancer patients, anthra-
cyclines use increased; this is probably also influenced
by the results of a meta-analysis by Gennari et al. [21].
There was an overall increase in anthracyclines use in
HER2-positive versus HER2-negative patients (absolute
increase: 9.4%); however, while anthracyclines alone were
prescribed equally between HER2-positive and HER2-
negative patients, there was higher use of anthracyclines
plus taxanes in HER2-positive versus HER2-negative
patients (absolute increase: 6.9%). This data is also con-
sistent with a meta-analysis conducted by De Laurentiis
et al. [22] which demonstrated that chemotherapy con-
taining anthracyclines plus taxanes is more effective than
anthracyclines alone in HER2-positive breast cancer.
Finally, patients treated with chemotherapy included
schedules with CMF-like regimen or AC/EC for four
cycles. Recently, EBCTCG demonstrated that these regi-
mens remain suboptimal schedules in terms of efficacy.
We know from EBCTCG metanalysis that more effective
chemotherapy regimens included anthracyclines with
doxorubicin with a dose of at least 60 mg/m2 per cycle
or epirubicin with a dose of at least 90 mg/m2 per cycle
with cumulative dose of more than 240 mg/m2 and
360 mg/m2, respectively, or regimens including anthra-
cyclines plus taxanes [23]. Overall, 25.3% of population
study was treated with CMF-like or AC/EC four cycles
and 12% with FEC for 6 cycles but with suboptimal epir-
ubicin dose per cycle (75 mg/m2). These data were con-
firmed also for particular sensitive disease to
chemotherapy, HER2-positive and triple negative, in
which suboptimal chemotherapy with CMF-like or AC/
EC for 4 cycles was prescribed in 24.2% and 22.2%, re-
spectively. FEC 6 cycles with epirubicin 75 mg/m2 was
adopted in 12.3% and 11.8%, respectively.
Conclusions
This observational study showed a possible 25% of over
prescription of adjuvant chemotherapy for early breast
cancer, particularly referred to luminal A biological sub-
type. Prognostic parameters (pT and pN) and only mar-
ginally HER2 were the principal determinants for the
prescription of the type of chemotherapy, with the use
of more effective regimen (anthracyclines and taxanes)
with increasing risk recurrence and HER2-positive. Sub-
optimal chemotherapy regimens (CMF-like or AC/E or
FEC with suboptimal epirubicin dose) were adopted in
at least one third of highly chemosensitive disease
(HER2-positve and triple negative).
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